Last $3.67 USD
Change Today -0.01 / -0.27%
Volume 36.2K
PSDV On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
Frankfurt
OTC US
As of 5:20 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

psivida corp (PSDV) Snapshot

Open
$3.63
Previous Close
$3.68
Day High
$3.74
Day Low
$3.53
52 Week High
10/2/13 - $5.60
52 Week Low
04/26/13 - $2.12
Market Cap
100.4M
Average Volume 10 Days
113.5K
EPS TTM
$-2.30
Shares Outstanding
27.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PSIVIDA CORP (PSDV)

psivida corp (PSDV) Related Businessweek News

No Related Businessweek News Found

psivida corp (PSDV) Details

pSivida Corp. develops products to deliver drugs and biologics primarily in the United States and the United Kingdom. The company, through its Durasert and BioSilicon technology platforms, focuses on the treatment of chronic diseases of the back of the eye. It offers ILUVIEN, an injectable sustained-release micro-insert delivering fluocinolone acetonide for the treatment of vision impairment associated with chronic diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company’s ILUVIEN is also studied in two Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It also develops Medidur, which is in Phase III clinical trials for the treatment of posterior uveitis; TBD that is in Phase I/II clinical trial for the treatment of glaucoma; and glaucoma latanoprost product candidate, which is an injectable bioerodible drug delivery micro-insert for the treatment of glaucoma and ocular hypertension. The company has strategic collaborations with Alimera Sciences, Inc.; Pfizer, Inc.; Bausch & Lomb Incorporated; Intrinsiq Materials Cayman Limited; and Enigma Therapeutics Limited. pSivida Corp. was founded in 1987 and is headquartered in Watertown, Massachusetts.

25 Employees
Last Reported Date: 09/27/13
Founded in 1987

psivida corp (PSDV) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $728.3K
Principal Financial & Accounting Officer and ...
Total Annual Compensation: $302.7K
Vice President of Corporate Affairs, General ...
Total Annual Compensation: $466.4K
Compensation as of Fiscal Year 2013.

psivida corp (PSDV) Key Developments

pSivida Corp. Announces Resubmission of New Drug Application to FDA for ILUVIEN

pSivida Corp. announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe. Alimera is awaiting the FDA's acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. pSivida will report that information when it becomes available.

pSivida Announces ILUVIEN(R) for DME Accepted by National Health Service Scotland

pSivida Corp. announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN(R) for use within the National Health Service (NHS) Scotland under a simple patient access scheme. ILUVIEN will be available in the NHS Scotland to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies in pseudophakic eyes. The NHS National Services Scotland has agreed to the patient access scheme in relation to the supply of ILUVIEN for this indication on behalf of all purchasing sites in the NHS in Scotland. Retreatment with ILUVIEN, which provides a therapeutic benefit for up to 36 months, will be covered when the patient has previously responded to ILUVIEN and vision has deteriorated to less than 20/32.

pSivida Corp. Announces Unaudited Consolidated Financial Results for Its Second Quarter and Six Months Ended December 31, 2013

pSivida Corp. announced unaudited consolidated financial results for its second quarter and six months ended December 31, 2013. Revenues for the quarter ended December 31, 2013 totaled $592,000 compared to $585,000 for the prior year period. Increased collaborative research and development revenue was offset by lower Retisert royalty income from Bausch & Lomb. Net loss was $3.5 million or $0.13 per basic and diluted share compared to a net loss of $2.6 million or $0.11 per basic and diluted share for the prior year quarter. The higher net loss in the second quarter of fiscal 2014 primarily reflected costs associated with its Phase III clinical trial of Medidur for posterior uveitis, which commenced in the quarter ended June 2013. Loss from operations was $3.54 million compared to $2.65 million reported a year ago. Loss before income taxes was $3.54 million compared to $2.64 million reported a year ago. Revenues for the six months ended December 31, 2013 totaled $1.2 million compared to $1.1 million for the six months ended December 31, 2012. The company reported a net loss of $7.2 million or $0.27 per basic and diluted share compared to a net loss of $5.2 million, or $0.23 per basic and diluted share, for the same period of the prior year. Loss from operations was $7.259 million compared to $5.24 million reported a year ago. Loss before income taxes was $7.257 million compared to $5.23 million reported a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PSDV:US $3.67 USD -0.01

PSDV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $165.65 USD +2.00
Novartis AG SFr.76.25 CHF -0.15
Regeneron Pharmaceuticals Inc $303.08 USD -8.60
View Industry Companies
 

Industry Analysis

PSDV

Industry Average

Valuation PSDV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 45.2x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PSIVIDA CORP, please visit www.psivida.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.